Investments
13Portfolio Exits
1
Want to inform investors similar to Cedar Point Capital about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest Cedar Point Capital News
Feb 25, 2020
Aria CV, Inc., a St. Paul, Minn.-based developer of medical devices treating Pulmonary Arterial Hypertension (PAH), completed a $31m Series B round of financing. The round was led by Xeraya Capital, with participation from Longview Ventures, Catalyst Health Ventures, BioStar Ventures, Cedar Point Capital, Frontcourt Group, and three strategic investors. As part of this financing, Jason Rushton will join Darshana Zaveri (Catalyst Health Ventures), Maria Berkman (Longview Ventures), Renee Masi (BioStar Ventures) and Dan Gladney, on the Board of Directors. The company intends to use the funds to conduct the first clinical study in the United States designed to evaluate long term implants of the Aria CV Pulmonary Hypertension System (Aria CV PH System) in PAH patients. The round was closed one week after the Aria CV PH System was granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA), which is intended to expedite the FDA review and approval of designated devices that may provide more effective treatment of life-threatening diseases. Founded in 2010 by Drs. John Scandurra and Karl Vollmers, following development work the two had done at the University of Minnesota’s Earl E. Bakken Medical Devices Center, and led by Dan Gladney, CEO and President, Aria CV has performed an acute first in human clinical study in Vienna, Austria and is now preparing for the U.S. clinical trial under the FDA’s Early Feasibility Study Program to evaluate long term implants in PAH patients. FinSMEs 25/02/2020
Cedar Point Capital Investments
13 Investments
Cedar Point Capital has made 13 investments. Their latest investment was in Aria CV as part of their Series B on January 1, 2020.

Cedar Point Capital Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
1/21/2020 | Series B | Aria CV | $31M | No | BioStar Capital, Broadview Ventures, Cedar Point Capital, Frontcourt Group, Undisclosed Investors, and Xeraya Capital | 3 |
12/7/2015 | Growth Equity | Medicom Health | $3M | Yes | 2 | |
7/24/2015 | Series A | Aria CV | $7.8M | Yes | 1 | |
6/28/2013 | Unattributed - V | |||||
4/10/2013 | Series E |
Date | 1/21/2020 | 12/7/2015 | 7/24/2015 | 6/28/2013 | 4/10/2013 |
---|---|---|---|---|---|
Round | Series B | Growth Equity | Series A | Unattributed - V | Series E |
Company | Aria CV | Medicom Health | Aria CV | ||
Amount | $31M | $3M | $7.8M | ||
New? | No | Yes | Yes | ||
Co-Investors | BioStar Capital, Broadview Ventures, Cedar Point Capital, Frontcourt Group, Undisclosed Investors, and Xeraya Capital | ||||
Sources | 3 | 2 | 1 |
Cedar Point Capital Portfolio Exits
1 Portfolio Exit
Cedar Point Capital has 1 portfolio exit. Their latest portfolio exit was Tactile Medical on July 28, 2016.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
7/28/2016 | IPO | Public | 6 |
Date | 7/28/2016 |
---|---|
Exit | IPO |
Companies | |
Valuation | |
Acquirer | Public |
Sources | 6 |
Cedar Point Capital Team
2 Team Members
Cedar Point Capital has 2 team members, including current President, Richard Nigon.
Name | Work History | Title | Status |
---|---|---|---|
Richard Nigon | President | Current | |
Name | Richard Nigon | |
---|---|---|
Work History | ||
Title | President | |
Status | Current |